



May 2013



HESI Annual Meeting. Registration is now [OPEN](#) and **FREE**. Join us on 11-13 June 2013 in Alexandria, Virginia for dynamic speakers, great science, and to help shape the future of HESI's scientific programs. Registration and additional information can be found [here](#).

HESI PATC / IFBiC Biotechnology Symposium. On 7-8 May 2013, the HESI Protein Allergenicity Technical Committee (PATC) and the ILSI International Food Biotechnology Committee (IFBiC) co-hosted a Biotechnology Update Symposium in Arlington, VA. The purpose of the symposium was to discuss priorities and challenges for safety assessment of products of agricultural biotechnology across the NAFTA region (Canada, Mexico, and the US). Fifty scientists from government, academia, and industry participated in the symposium. Regulatory science perspectives were presented by representatives from the Canadian Food Inspection Agency, Health Canada, the Mexico Intersecretarial Commission of Biosafety and Genetically Modified Organisms, the US Department of Agriculture, the US Food and Drug Administration, and the US Environmental Protection Agency. Of particular interest was a half-day session devoted to selected academic research on food allergy and genetically engineered food which is funded by the US EPA's Science to Achieve Results (STAR) grants program. Symposium materials, video recordings of presentations, and other information are available [here](#). The HESI PATC and IFBiC typically co-host a NAFTA biotechnology meeting every two to three years. For more information, contact Ms. Nancy G. Doerrer (ndoerrer@hesiglobal.org).

HESI Genomics Workshop. The HESI Application of Genomics to Mechanism-Based Risk Assessment Technical Committee and Maastricht University co-organized a workshop on Moving Forward in Human Cancer Risk Assessment in the Genomics Era 2.0 held May 16-17, 2013 at the OECD Congress Center in Paris, France. An international group of approximately 60 attendees from industrial, academic, and government institutions convened to discuss progress in human carcinogenesis safety evaluation strategies and cancer risk assessment. Workshop sessions addressed utility of toxicogenomics approaches in risk assessment of genotoxicity findings and of chemical carcinogenicity as well as informatics challenges. For additional information, contact Dr. Raegan O'Lone, rolone@hesiglobal.org.



New Publication from the Cardiac Safety Committee. Pierson JB, Berridge BR, Brooks MB, Dreher K, Koerner, J, Schultze AE, Sarazan RD, Valentin J, Vargas HM, Pettit SD. (2013) [A public-private consortium advances cardiac safety evaluation: Achievements of the HESI Cardiac Safety Technical Committee](#). J Pharmacol Toxicol Methods. Available online April 6, 2013.

UPCOMING HESI WORKSHOPS



HESI RISK21 Workshop in Japan.

On 5 July 2013, the HESI RISK21 Technical Committee will hold a workshop at TKP Otemachi Conference Center, in Tokyo, Japan. The purpose of the workshop is to share the RISK21 strategies and approaches for chemical risk assessment and discuss their applicability in Japan and globally. If you are interested, please contact Dr. Michelle Embry (membr@hesiglobal.org) or Ms. Ayako Takei (atakei@hesiglobal.org), HESI Scientific Advisor in Japan.

HESI-CSRC-FDA Workshop. Registration is now [OPEN](#). On 23 July 2013, HESI, CSRC and FDA are hosting the workshop, [Rechanneling the Current Cardiac Risk Paradigm: Arrhythmia Risk Assessment During Drug Development Without the Thorough QT Study](#), at FDA's White Oak Facility. The workshop will examine and discuss a new paradigm, focusing on a comprehensive assessment of ion channel effects to determine actual proarrhythmic risk. This new approach has the real potential to obviate the need for clinical Thorough QT studies, making CV risk assessment more efficient. Please contact Ms. Jennifer Pierson (jpierson@hesiglobal.org) for more information.



HESI at IUTOX. The Risk Assessment in the 21st Century (RISK21) Technical Committee and the Genetic Toxicology Technical Committee (GTTC) have organized and sponsored symposia at the International Congress of Toxicology 2013 (ICT 2013) which will be held in Seoul, South Korea on 30 June – 4 July 2013.

Symposium: RISK21: Accurate, Resource Appropriate Risk Assessment, on 1 July 2013 at 14:00-15:30.

- Prof. Alan Boobis (Imperial College London, UK), "Why the need for RISK21?"
- Dr. Timothy Pastoor (Syngenta, USA), "The RISK21 Roadmap and Matrix"
- Dr. Douglas Wolf (US EPA, USA), "RISK21 Case Studies"
- Prof. Angelo Moretto (University of Milan, Italy), "Applications to Cumulative Risk"

Symposium: Are There Thresholds for Genotoxicity?, on 2 July 2013 at 15:30 - 17:00.

- Dr. Anthony Lynch (GlaxoSmithKline, UK), "Impact of Moving From Qualitative to Quantitative Approach on Genotoxicity Risk Assessment"
- Dr. Bhaskar Gollapudi (Retired Dow Chemical Co., USA), "A Critical Assessment of Low Dose Response in Genetic Toxicology"
- Prof. George Johnson (Swansea University, UK), "Mechanisms Underlying the Non-Linear Dose-Responses for DNA-Reactive Genotoxicants"
- Dr. Takehiko Nohmi (National Institute of Health Sciences, Japan), "DNA Repair and Translesion DNA Synthesis as Constituents of "Threshold" of Genotoxicity"
- Dr. Shoji Fukushima (Japan Bioassay Research Center, Japan), "Threshold of Genotoxic Carcinogens: Conclusion from Mechanism-Based Carcinogenicity Studies"



HESI at Green Chemistry

Conference. The Sustainable Alternatives Subcommittee will have a strong presence at the 17th Annual Green

Chemistry & Engineering Conference on 18-20 June 2013 in North Bethesda, MD. Three presentations will be given by Dr. Derek Muir (Environment Canada), Prof. Royce Francis (George Washington University) and Dr. David Constable (ACS Green Chemistry Institute®) on behalf of the subcommittee during the "What is an Alternative Assessment?" session. HESI is also sponsoring the ACS GCI Roundtable Poster Reception and will be on hand to discuss a poster about the subcommittee and HESI.

ILSI Health and Environmental Sciences Institute (HESI)
1156 Fifteenth Street, NW
Suite 200
Washington, DC 20005-1743
202.659.3306 phone
202.659.3617 fax

Please visit us at our [website](#), on [YouTube](#) or follow us on [Twitter](#) to receive announcements on new publications, upcoming meetings and conferences, and other news.



HESI at Teratology Society. The Developmental and Reproductive Toxicology (DART) Technical Committee is co-sponsoring a symposium on "Communication of Risk for Medication Use in Pregnancy and Lactation" on 24 June 2013 in Tucson, AZ at the Teratology Society Annual Meeting. Dr. Jane Stewart (AstraZeneca), DART co-chair, is one of the symposium chairpersons.



FROM THE EXECUTIVE DIRECTOR

Global reach, multi-disciplinary relevance. In this month's issue alone, we see HESI's scientific leadership featured in the US, Europe, Korean and Japan, and at such venues as the OECD Congress Center in Paris, France and the US FDA Headquarters Facility in White Oak, Maryland. Consider this month's sampling of HESI initiatives – green chemistry, developmental toxicology, carcinogenomics, cardiovascular safety, risk assessment methodologies, and more. HESI's science continues to translate the highest quality research into meaningful applications for human and environmental health and safety.

Spir D. Robit